Cas no 472-15-1 (Betulinic acid)
Betulinic acid Chemical and Physical Properties
Names and Identifiers
-
- betulinic acid
- 3BETA-HYDROXY-20(29)-LUPENE-28-OIC ACID
- 3B-HYDROXY-20(29)-LUPENE-28-OIC ACID
- 3-B-HYDROXY-LUPA-20(30)-ENE 28-OIC ACID
- BETULIC ACID
- LUP-20(29)-EN-28-OIC ACID, 3-HYDROXY-, (3B)-
- Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-
- BETULICACID: LUP-20(29)-EN-28-OICACID, 3-HYDROXY-, (3B)-,
- Betulinic
- 3β-hydroxy-20(29)-lupaene-28-oic acid
- BETULINIC ACID(P)
- Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3β)-
- BETULINIC ACID(P) - [Discontinued]
- BETULINIC ACID(P) - [Discontinued] PrintBack
- BETULINIC ACID(RG)
- ALS-357
- Gratiolone
- Lupatic acid
- Melaleucin
- Platanol
- Mairin
- 3beta-Hydroxy-20(29)-lupaene-28-oic acid
- NSC677578
- 4G6A18707N
- SMR000445624
- Betulinicacid
- Platanolic acid
- Prestwick3_000417
- Q-100500
- 3beta-hydroxylup-20(29)-en-28-oic acid
- HMS1989P09
- SR-01000779609
- DS-15257
- s3603
- Betulinic acid, technical grade, 90%
- CHEMBL269277
- NCGC00163409-02
- MLS006011257
- Betulinic acid, analytical standard
- SPBio_002313
- Prestwick1_000417
- (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-Hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-eicosahydro-cyclopenta[a]chrysene-3a-carboxylic acid
- BPBio1_000412
- NCGC00163409-03
- CCRIS 6748
- 06L
- (1R,3 aS,5aR,5bR,7aR,9S,11aR,11bR,13 aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid
- (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid
- Betulinic Acid, 24
- 3-Hydroxylup-20(29)-en-28-oic acid
- BRD-K45401373-001-05-0
- QGJZLNKBHJESQX-FZFNOLFKSA-N
- Prestwick0_000417
- (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylicacid
- HMS2232K03
- HMS1791P09
- MFCD00009619
- C08619
- DTXSID80861974
- UNII-4G6A18707N
- NS00042781
- (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
- Lup-20(29)-en-28-oic acid, 3beta -hydroxy-
- 3beta-Hydroxy-lup-20(29)-en-28-oic acid
- HMS2096C16
- SMP2_000205
- CHEBI:3087
- BETULINIC ACID [MI]
- Prestwick2_000417
- Betulinic acid, >=98% (HPLC)
- cid_64971
- (3beta)-3-Hydroxy-lup-20(29)-en-28-oic Acid
- beta-betulinic acid
- Q384111
- HMS1569C16
- NCGC00163409-09
- .beta.-betulinic acid
- betulinic-acid
- MLS000728510
- (+)-(3?)-3-Hydroxylup-20(29)-en-28-oic acid
- AKOS015920276
- BSPBio_000374
- HMS3402P09
- (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
- Lupatic acid;Betulic acid
- BRD-K45401373-001-22-5
- DB12480
- (3beta)-3-hydroxylup-20(29)-en-28-oic acid
- Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3.beta.)-
- CS-1216
- NSC-677578
- NSC113090
- BSPBio_001587
- NSC 677578
- (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-17-hydroxy-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0^{2,10}.0^{5,9}.0^{14,19}]henicosane-5-carboxylic acid
- C30H48O3
- 472-15-1
- SCHEMBL61767
- Lup-20(29)-en-28-oic acid, 3beta-hydroxy-
- (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylicacid
- NSC 113090
- GTPL3945
- BP-25391
- HY-10529
- (3.BETA.)-3-HYDROXYLUP-20(29)-EN-28-OIC ACID
- BDBM23208
- SR-01000779609-3
- CCG-208159
- EINECS 207-448-8
- Prestwick_95
- BETULINIC ACID [INCI]
- LMPR0106140004
- RL9-080
- NSC-113090
- 3-Hydroxy-(3beta)-Lup-20(29)-en-28-oic acid
- HB3799
- Lup-20(29)-en-28-oic acid, 3.beta.-hydroxy-
- Lupatic acid; Betulic acid; Mairin;ALS357; ALS 357; ALS-357
- 9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
- BCP08998
- AKOS025295351
- 1H-Cyclopenta[a]chrysene, lup-20(29)-en-28-oic acid deriv.
- LS-15294
- acs.jmedchem.1c00409_ST.478
- 38736-77-5
- BDBM512883
- SCHEMBL4143519
- QGJZLNKBHJESQX-UHFFFAOYSA-N
- 3-Hydroxylup-20(29)-en-28-oic acid #
- NCI60_000293
- 3-epi-betulinic acid
- ConMedNP.2804
- ConMedNP.2805
- ConMedNP.2806
- ConMedNP.2807
- ConMedNP.2811
- ConMedNP.2801
- ConMedNP.2812
- ConMedNP.2802
- ConMedNP.2803
- ConMedNP.2810
- MLS001097660
- SMR000578092
- MLSMR
- ConMedNP.2808
- ConMedNP.2809
- Betulinic acid technical grade, 90%
- Birch bark extract/β-Amyrin/betulinic acid
- Betulinic acid
-
- MDL： MFCD00009619
- Inchi： 1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
- InChI Key： QGJZLNKBHJESQX-FZFNOLFKSA-N
- SMILES： O([H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]([H])(C1(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]1(C([H])([H])[H])[C@]2([H])C([H])([H])C([H])([H])[C@]2([H])[C@@]3([H])[C@]([H])(C(=C([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]3(C(=O)O[H])C([H])([H])C([H])([H])[C@@]12C([H])([H])[H]
Computed Properties
- Exact Mass: 456.36000
- Monoisotopic Mass: 456.36034539 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 33
- Rotatable Bond Count: 2
- Complexity: 861
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 10
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- XLogP3: 8.2
- Topological Polar Surface Area: 57.5
- Molecular Weight: 456.7
Experimental Properties
- Color/Form: Powder
- Density: 1.0650
- Melting Point: 295-298?°C (dec.) (lit.)
- Boiling Point: 550°C at 760 mmHg
- Flash Point: 300.5 oC
- Refractive Index: 7.8 ° (C=0.9, Pyridine)
- Solubility: 可溶于DMSO（高達25mg/ml）或乙醇（高達25mg/ml）。
- PSA: 57.53000
- LogP: 7.08950
- Solubility: Not determined
- Merck: 1190
- Specific Rotation: D25 +7.5° (c = 0.37 in pyridine)
- Optical Activity: [α]20/D +7.8°, c =?0.9 in pyridine
- pka: 4.61±0.70(Predicted)
Betulinic acid Security Information
- Signal Word：Warning
- Hazard Statement： H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Safety Instruction： 24/25
-
Hazardous Material Identification：
- Storage Condition：4°C, protect from light
Betulinic acid Customs Data
- HS CODE：2942000000
- Customs Data：
China Customs Code:
2918199090Overview:
HS: 2918199090. Other alcohol containing but not other oxy carboxylic acids(Including its anhydride\Acyl halide\Peroxides, peroxyacids and derivatives of this tax number). VAT:17.0%. Tax refund rate:9.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%
Declaration elements:
Product Name, component content, use to
Summary:
2918199090 other carboxylic acids with alcohol function but without other oxygen function, their anhydrides, halides, peroxides, peroxyacids and their derivatives.Supervision conditions:None.VAT:17.0%.Tax rebate rate:9.0%.MFN tariff:6.5%.General tariff:30.0%
Betulinic acid Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 855057-100MG |
Betulinic acid |
472-15-1 | 90% | 100mg |
￥851.75 | 2023-11-19 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 855057-500MG |
Betulinic acid |
472-15-1 | 90% | 500mg |
￥2282.23 | 2023-11-19 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 91466-10MG |
Betulinic acid |
472-15-1 | 10mg |
￥1759.06 | 2023-10-21 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | PHL89529-50MG |
Betulinic acid |
472-15-1 | 50mg |
￥2903.4 | 2023-09-09 | ||
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | B804029-1g |
Betulinic acid |
472-15-1 | 97% | 1g |
￥1,700.00 | 2022-09-02 | |
| TRC | B330250-100mg |
Betulinic Acid |
472-15-1 | 100mg |
$ 63.00 | 2023-04-18 | ||
| TRC | B330250-250mg |
Betulinic Acid |
472-15-1 | 250mg |
$ 69.00 | 2023-04-18 | ||
| TRC | B330250-500mg |
Betulinic Acid |
472-15-1 | 500mg |
$ 108.00 | 2023-04-18 | ||
| TRC | B330250-1g |
Betulinic Acid |
472-15-1 | 1g |
$ 170.00 | 2023-04-18 | ||
| TRC | B330250-2g |
Betulinic Acid |
472-15-1 | 2g |
$ 201.00 | 2023-04-18 |
Betulinic acid Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Betulinic acid Related Literature
-
Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
-
Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
-
Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
-
Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
-
M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
Related Categories
- Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
- Natural Products and Extracts Plant Extracts Plant based Sarcomphalus joazeiro
- Natural Products and Extracts Plant Extracts Plant based Retanilla trinervia
- Natural Products and Extracts Plant Extracts Plant based Physopsis viscida
- Natural Products and Extracts Plant Extracts Plant based Harpalyce brasiliana
- Natural Products and Extracts Plant Extracts Plant based Condea albida
- Triterpenoids
- Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances
Additional information on Betulinic acid
Betulinic acid (CAS No. 472-15-1): A Comprehensive Overview of Its Chemistry, Biology, and Emerging Applications
Betulinic acid, with the chemical formula C30H48O3 and CAS number 472-15-1, is a triterpenoid compound derived from the bark of the white birch tree (*Betula pendula*). This naturally occurring substance has garnered significant attention in the field of pharmaceutical research due to its diverse biological activities and potential therapeutic applications. Over the years, extensive studies have elucidated its chemical structure, mechanisms of action, and pharmacological properties, making it a subject of intense interest for scientists and researchers worldwide.
The chemical structure of Betulinic acid features a lupane skeleton with a hydroxyl group at the C-3 position and a carbonyl group at the C-28 position. This unique configuration contributes to its remarkable reactivity and biological interactions. The compound is primarily found in birch bark, where it exists as an aglycone before being converted into betulinic acid through enzymatic or chemical processes. Its solubility profile in organic solvents makes it amenable to various extraction and purification techniques, facilitating its use in both laboratory and industrial settings.
In recent years, Betulinic acid has been extensively studied for its potential anti-inflammatory, antioxidant, anti-microbial, and anti-cancer properties. One of the most compelling areas of research has been its role in cancer therapy. Preclinical studies have demonstrated that Betulinic acid can induce apoptosis in various cancer cell lines by disrupting mitochondrial function and inhibiting key signaling pathways involved in tumor growth. Furthermore, its ability to modulate immune responses has opened new avenues for developing immunotherapeutic strategies against cancer.
The anti-cancer effects of Betulinic acid are attributed to its ability to activate stress signals such as p53 and PERK, which are critical for cell cycle regulation and apoptosis. Additionally, it has been shown to inhibit the activity of enzymes like topoisomerase I and II, which are essential for DNA replication in cancer cells. These mechanisms make Betulinic acid a promising candidate for combination therapies with existing chemotherapeutic agents.
Another significant area of research has focused on the anti-inflammatory properties of Betulinic acid. Chronic inflammation is a hallmark of many diseases, including arthritis, cardiovascular disorders, and neurodegenerative conditions. Studies have shown that Betulinic acid can suppress the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 by inhibiting key transcription factors like NF-κB. This makes it a potential therapeutic agent for managing inflammatory diseases without the side effects associated with conventional anti-inflammatory drugs.
The antioxidant properties of Betulinic acid have also been extensively studied. Reactive oxygen species (ROS) play a crucial role in cellular damage and aging. By scavenging free radicals and enhancing the activity of endogenous antioxidant enzymes like superoxide dismutase (SOD) and catalase, Betulinic acid helps protect cells from oxidative stress. This property has implications not only in preventing age-related diseases but also in mitigating the side effects of radiation therapy in cancer patients.
In addition to its biological activities, Betulinic acid has shown promise in combating microbial infections. Research indicates that it can inhibit the growth of various bacteria, fungi, and viruses by disrupting their cell membranes or interfering with essential metabolic pathways. This broad-spectrum antimicrobial activity makes it an attractive candidate for developing novel antibiotics and antiviral agents.
The pharmacokinetic profile of Betulinic acid presents both challenges and opportunities for clinical applications. While its oral bioavailability is relatively low due to rapid metabolism by cytochrome P450 enzymes, recent advancements in drug delivery systems have shown promise in enhancing its efficacy. Liposomal formulations, nanocarriers, and prodrugs are being explored to improve its absorption and target specificity.
The safety profile of Betulinic acid has been evaluated through preclinical studies using animal models. These studies have revealed that it exhibits low toxicity at therapeutic doses with minimal side effects on major organs. However, further clinical trials are needed to confirm these findings in human populations.
The future prospects for Betulinic acid are promising as ongoing research continues to uncover new therapeutic applications. Its natural origin makes it an environmentally friendly compound with minimal ecological impact compared to synthetic drugs. Additionally, its versatility in targeting multiple disease pathways suggests that it could be repurposed for treating a wide range of conditions beyond cancer and inflammation.
In conclusion,< strong>Betulinic acid (CAS No. 472-15-1) is a multifaceted compound with significant potential in pharmaceutical applications. Its unique chemical structure combined with diverse biological activities positions it as a valuable asset in drug discovery efforts aimed at addressing some of the most pressing health challenges today.
472-15-1 (Betulinic acid) Related Products
- 2572-03-4('Melaleucicsaeure')
- 102636-98-6(Lup-20(29)-en-28-oicacid, 3,27-dihydroxy-, (3b)-)
- 90806-27-2(N/A)
- 99877-98-2((3alpha,11alph)-3,11-Dihydroxy-24-nor-20(29)-lupen-28-oic acid)
- 74635-53-3((ent-12beta)-12-Hydroxy-16-kauren-19-oic acid)
- 1041795-45-2(N/A)
- 198014-94-7(Lup-20(29)-en-27-oic acid, 3-hydroxy-, (3a)-)
- 107014-55-1(betulinic acid)
- 75154-03-9((ent-12beta)-12-Hydroxy-16-kauren-19-oic acid)
- 126778-79-8(Kaur-16-en-18-oic acid,7-hydroxy-, (4b,7b)- (9CI))
